Education/CredentialsMSc: The Ohio State University, (Translational Data Analytics)PhD: The Ohio State University, (Microbiology) Contact Information CARE/Crawley 7871 Office 513-558-2598 Email elgamasa@ucmail.uc.edu Peer Reviewed Publications Jeremy E, Artiga E, Elgamal S, Cheney CM, Eicher D, Zalponik K, Orwick S, Mao HCC, Wasmuth R, Harrington BK, Mustonen A, Beshay P, Halley P, Castro C, Williams KE, Hing ZA, Chen TL, Lucas CR, Vantangoli NJ, Lapalombella R, Grieselhuber NR, Mo XM, Hertlein E, Muthusamy N, Mundy-Bosse BL, Byrd JC, Larkin K 2025. CD37 in acute myeloid leukemia: a novel surface target for drug delivery Blood advances, 9 1, 1Leiva, Lorenzo Eugenio; Elgamal, Sara; Leidel, Sebastian A; Orellana, Omar; Ibba, Michael; Katz, Assaf 2022. Oxidative stress strongly restricts the effect of codon choice on the efficiency of protein synthesis in Escherichia coli. Frontiers in microbiology, 13 , 1042675Elgamal, Sara; Cocucci, Emanuele; Sass, Ellen J; Mo, Xiaokui M; Blissett, Angela R; Calomeni, Edward P; Rogers, Kerry A; Woyach, Jennifer A; Bhat, Seema A; Muthusamy, Natarajan; Johnson, Amy J; Larkin, Karilyn T; Byrd, John C 2021. Optimizing extracellular vesicles' isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant. JCI insight, 6 15, Hu, Eileen Y; Do, Priscilla; Goswami, Swagata; Nunes, Jessica; Chiang, Chi-Ling; Elgamal, Sara; Ventura, Ann M; Cheney, Carolyn; Zapolnik, Kevan; Williams, Erich; Mani, Rajeswaran; Frissora, Frank; Mo, Xiaokui; Waldmeier, Lorenz; Beerli, Roger R; Peng, Haiyong; Rader, Christoph; Long, Meixiao; Grawunder, Ulf; Byrd, John C; Muthusamy, Natarajan 2021. The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Blood advances, 5 16, 3152-3162Elgamal, Sara; Colombo, Federico; Cottini, Francesca; Byrd, John C; Cocucci, Emanuele 2020. Imaging intercellular interaction and extracellular vesicle exchange in a co-culture model of chronic lymphocytic leukemia and stromal cells by lattice light-sheet fluorescence microscopy. Methods in enzymology, 645 , 79-107Elgamal, Sara; Artsimovitch, Irina; Ibba, Michael 2016. Maintenance of Transcription-Translation Coupling by Elongation Factor P. mBio, 7 5, Elgamal, Sara; Katz, Assaf; Hersch, Steven J; Newsom, David; White, Peter; Navarre, William Wiley; Ibba, Michael 2014. EF-P dependent pauses integrate proximal and distal signals during translation. PLoS genetics, 10 8, e1004553 Abstract Publications Elgamal S, Furby C, Long M, Fyock K, Sesterhenn TM, Johnstone ME, Pan J, Rai SN, Khvat A, Karapetian R, Ryakhovskiy A, Bulanova E, Parchinsky V, Savchuk N, Dukes I, Burd A, Hertlein EK, Byrd JC. 2024. Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies. The 66th American Society of Hematology (ASH) Annual Meeting and Exposition Blood, 144 Supplement 1, 2783Sharpe C, Elgamal S, Fobare S, Furby C, Long M, Bryant K, Cheney C, Lerma JR, Johnstone ME, Orry A, Lam PC-H, Abagyan R, Kysil V, Gukasyan H, Mitkin O, Karapetian R, Ryakhovskiy A, Bulanova E, Parchinsky V, Ivachtchenko A, Dokukina K, Pushechnikov A, Savchuk N, Dukes I, Burd A, Hertlein EK, Byrd JC. 2023. A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax Blood, 142 Supplement 1, 4153Elgamal S, Clevenger T, Gulrajani M, Cheung J, Jeremy EG, Fobare S, Orwick S, Sass EJ, Hertlein E, Larkin KT, Covey T, Rothbaum WP, Byrd JC 2022. Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies Blood, 140 Supplement 1, 5936
Peer Reviewed Publications Jeremy E, Artiga E, Elgamal S, Cheney CM, Eicher D, Zalponik K, Orwick S, Mao HCC, Wasmuth R, Harrington BK, Mustonen A, Beshay P, Halley P, Castro C, Williams KE, Hing ZA, Chen TL, Lucas CR, Vantangoli NJ, Lapalombella R, Grieselhuber NR, Mo XM, Hertlein E, Muthusamy N, Mundy-Bosse BL, Byrd JC, Larkin K 2025. CD37 in acute myeloid leukemia: a novel surface target for drug delivery Blood advances, 9 1, 1Leiva, Lorenzo Eugenio; Elgamal, Sara; Leidel, Sebastian A; Orellana, Omar; Ibba, Michael; Katz, Assaf 2022. Oxidative stress strongly restricts the effect of codon choice on the efficiency of protein synthesis in Escherichia coli. Frontiers in microbiology, 13 , 1042675Elgamal, Sara; Cocucci, Emanuele; Sass, Ellen J; Mo, Xiaokui M; Blissett, Angela R; Calomeni, Edward P; Rogers, Kerry A; Woyach, Jennifer A; Bhat, Seema A; Muthusamy, Natarajan; Johnson, Amy J; Larkin, Karilyn T; Byrd, John C 2021. Optimizing extracellular vesicles' isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant. JCI insight, 6 15, Hu, Eileen Y; Do, Priscilla; Goswami, Swagata; Nunes, Jessica; Chiang, Chi-Ling; Elgamal, Sara; Ventura, Ann M; Cheney, Carolyn; Zapolnik, Kevan; Williams, Erich; Mani, Rajeswaran; Frissora, Frank; Mo, Xiaokui; Waldmeier, Lorenz; Beerli, Roger R; Peng, Haiyong; Rader, Christoph; Long, Meixiao; Grawunder, Ulf; Byrd, John C; Muthusamy, Natarajan 2021. The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Blood advances, 5 16, 3152-3162Elgamal, Sara; Colombo, Federico; Cottini, Francesca; Byrd, John C; Cocucci, Emanuele 2020. Imaging intercellular interaction and extracellular vesicle exchange in a co-culture model of chronic lymphocytic leukemia and stromal cells by lattice light-sheet fluorescence microscopy. Methods in enzymology, 645 , 79-107Elgamal, Sara; Artsimovitch, Irina; Ibba, Michael 2016. Maintenance of Transcription-Translation Coupling by Elongation Factor P. mBio, 7 5, Elgamal, Sara; Katz, Assaf; Hersch, Steven J; Newsom, David; White, Peter; Navarre, William Wiley; Ibba, Michael 2014. EF-P dependent pauses integrate proximal and distal signals during translation. PLoS genetics, 10 8, e1004553
Jeremy E, Artiga E, Elgamal S, Cheney CM, Eicher D, Zalponik K, Orwick S, Mao HCC, Wasmuth R, Harrington BK, Mustonen A, Beshay P, Halley P, Castro C, Williams KE, Hing ZA, Chen TL, Lucas CR, Vantangoli NJ, Lapalombella R, Grieselhuber NR, Mo XM, Hertlein E, Muthusamy N, Mundy-Bosse BL, Byrd JC, Larkin K 2025. CD37 in acute myeloid leukemia: a novel surface target for drug delivery Blood advances, 9 1, 1Leiva, Lorenzo Eugenio; Elgamal, Sara; Leidel, Sebastian A; Orellana, Omar; Ibba, Michael; Katz, Assaf 2022. Oxidative stress strongly restricts the effect of codon choice on the efficiency of protein synthesis in Escherichia coli. Frontiers in microbiology, 13 , 1042675Elgamal, Sara; Cocucci, Emanuele; Sass, Ellen J; Mo, Xiaokui M; Blissett, Angela R; Calomeni, Edward P; Rogers, Kerry A; Woyach, Jennifer A; Bhat, Seema A; Muthusamy, Natarajan; Johnson, Amy J; Larkin, Karilyn T; Byrd, John C 2021. Optimizing extracellular vesicles' isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant. JCI insight, 6 15, Hu, Eileen Y; Do, Priscilla; Goswami, Swagata; Nunes, Jessica; Chiang, Chi-Ling; Elgamal, Sara; Ventura, Ann M; Cheney, Carolyn; Zapolnik, Kevan; Williams, Erich; Mani, Rajeswaran; Frissora, Frank; Mo, Xiaokui; Waldmeier, Lorenz; Beerli, Roger R; Peng, Haiyong; Rader, Christoph; Long, Meixiao; Grawunder, Ulf; Byrd, John C; Muthusamy, Natarajan 2021. The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Blood advances, 5 16, 3152-3162Elgamal, Sara; Colombo, Federico; Cottini, Francesca; Byrd, John C; Cocucci, Emanuele 2020. Imaging intercellular interaction and extracellular vesicle exchange in a co-culture model of chronic lymphocytic leukemia and stromal cells by lattice light-sheet fluorescence microscopy. Methods in enzymology, 645 , 79-107Elgamal, Sara; Artsimovitch, Irina; Ibba, Michael 2016. Maintenance of Transcription-Translation Coupling by Elongation Factor P. mBio, 7 5, Elgamal, Sara; Katz, Assaf; Hersch, Steven J; Newsom, David; White, Peter; Navarre, William Wiley; Ibba, Michael 2014. EF-P dependent pauses integrate proximal and distal signals during translation. PLoS genetics, 10 8, e1004553
Abstract Publications Elgamal S, Furby C, Long M, Fyock K, Sesterhenn TM, Johnstone ME, Pan J, Rai SN, Khvat A, Karapetian R, Ryakhovskiy A, Bulanova E, Parchinsky V, Savchuk N, Dukes I, Burd A, Hertlein EK, Byrd JC. 2024. Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies. The 66th American Society of Hematology (ASH) Annual Meeting and Exposition Blood, 144 Supplement 1, 2783Sharpe C, Elgamal S, Fobare S, Furby C, Long M, Bryant K, Cheney C, Lerma JR, Johnstone ME, Orry A, Lam PC-H, Abagyan R, Kysil V, Gukasyan H, Mitkin O, Karapetian R, Ryakhovskiy A, Bulanova E, Parchinsky V, Ivachtchenko A, Dokukina K, Pushechnikov A, Savchuk N, Dukes I, Burd A, Hertlein EK, Byrd JC. 2023. A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax Blood, 142 Supplement 1, 4153Elgamal S, Clevenger T, Gulrajani M, Cheung J, Jeremy EG, Fobare S, Orwick S, Sass EJ, Hertlein E, Larkin KT, Covey T, Rothbaum WP, Byrd JC 2022. Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies Blood, 140 Supplement 1, 5936
Elgamal S, Furby C, Long M, Fyock K, Sesterhenn TM, Johnstone ME, Pan J, Rai SN, Khvat A, Karapetian R, Ryakhovskiy A, Bulanova E, Parchinsky V, Savchuk N, Dukes I, Burd A, Hertlein EK, Byrd JC. 2024. Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies. The 66th American Society of Hematology (ASH) Annual Meeting and Exposition Blood, 144 Supplement 1, 2783Sharpe C, Elgamal S, Fobare S, Furby C, Long M, Bryant K, Cheney C, Lerma JR, Johnstone ME, Orry A, Lam PC-H, Abagyan R, Kysil V, Gukasyan H, Mitkin O, Karapetian R, Ryakhovskiy A, Bulanova E, Parchinsky V, Ivachtchenko A, Dokukina K, Pushechnikov A, Savchuk N, Dukes I, Burd A, Hertlein EK, Byrd JC. 2023. A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax Blood, 142 Supplement 1, 4153Elgamal S, Clevenger T, Gulrajani M, Cheung J, Jeremy EG, Fobare S, Orwick S, Sass EJ, Hertlein E, Larkin KT, Covey T, Rothbaum WP, Byrd JC 2022. Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies Blood, 140 Supplement 1, 5936